▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

QuidelOrtho Reports First Quarter 2024 Financial Results

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, an...

Business Wire

- Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue -
- Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings -
- Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer -

First Quarter 2024 Results and Recent Highlights

  • Revenue was $711 million, as reported:
    • Non-respiratory revenue was flat at $574 million compared to the prior year period, as reported and in constant currency
      • Excluding the one-time third-party settlement of $21 million in the prior year period, non-respiratory revenue grew 3% as reported and 4% on a constant currency basis
    • Respiratory revenue was $137 million, a 48% decrease as reported and in constant currency, primarily due to lower COVID-19 revenue in the first quarter of 2024 compared to the prior year period
      • Excluding COVID-19-related government orders of $143 million in Q1 2023 and $7 million in Q1 2024, which are not expected to recur, respiratory revenue grew 6% as reported and in constant currency
  • Secured credit agreement amendment to provide additional flexibility through 2027
  • Appointed Brian J. Blaser as President and Chief Executive Officer, effective May 6, 2024

SAN DIEGO: QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024.

“During the first quarter, we achieved solid business performance with 6% top-line constant currency revenue growth across our global regions, excluding COVID-19 revenue,” said Michael S. Iskra, EVP and Chief Commercial Officer, QuidelOrtho. “Additionally, we have been steadfast in implementing company-wide cost initiatives, including margin restoration, which includes headcount reductions that are expected to deliver approximately $100 million in annualized savings. While these actions are never easy, they are a necessary step in positioning the Company for durable long-term growth.”

First Quarter 2024

The Company reported total revenue for the first quarter of 2024 of $711 million, compared to $846 million in the prior year period. The decrease in total revenue was primarily due to lower COVID-19 revenue in the first quarter of 2024 compared to the prior year period. Foreign currency translation did not significantly impact first quarter 2024 results. GAAP diluted loss per share for the first quarter of 2024 was $25.50, compared to diluted earnings per share (“EPS”) of $0.73 in the prior year period. GAAP operating loss for the first quarter of 2024 was $1.76 billion, compared to operating income of $100 million in the prior year period. The first quarter of 2024 GAAP operating loss included a non-cash goodwill impairment charge of approximately $1.74 billion for the North America reporting unit due to the decrease in the estimated fair value, which was consistent with the decline in the Company’s market capitalization during the three months ended March 31, 2024. As a result of the goodwill impairment charge, GAAP operating margin was (247%) compared to 12% in the prior year period. First quarter 2024 results included $23 million in integration-related charges.

Adjusted diluted EPS for the first quarter of 2024 was $0.44, compared to $1.80 in the prior year period. Adjusted EBITDA was $132 million, compared to $245 million in the prior year period. Adjusted EBITDA margin was 19%, compared to 29% in the prior year period. The year-over-year change in adjusted diluted EPS and adjusted EBITDA was primarily due to lower COVID-19 revenue.

Fiscal Year 2024 Financial Guidance

Following the appointment of Brian J. Blaser as President and Chief Executive Officer, QuidelOrtho is suspending its 2024 financial guidance while it assesses the business under its new President and Chief Executive Officer. The Company plans to provide an update in today’s earnings conference call.

Conference Call Information

QuidelOrtho will hold a conference call today at 2:00 p.m. PDT / 5:00 p.m. EDT to discuss its financial results for the first quarter ended March 31, 2024. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or +1 929-526-1599 (international) and entering Conference ID number 295379.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website, under the “Events & Presentations” section.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial, integration, transformation and other strategic goals, future financial condition and operating results, including results of cost initiatives and operating flexibility achieved by the credit agreement amendment, and other future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: supply chain, production, logistics, distribution and labor disruptions and challenges; the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc; and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those discussed in QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”), including under Part I, Item 1A, “Risk Factors” of the Form 10-K. You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Non-GAAP Financial Measures

This press release contains financial measures, including but not limited to “constant currency” revenue and revenue changes, “constant currency, ex-COVID-19” revenue and revenue changes, revenue ex-COVID-19, “adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA” and “adjusted EBITDA margin,” which are considered non-GAAP financial measures under applicable rules and regulations of the Commission. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). “Constant currency” revenue and revenue changes, “constant currency, ex-COVID-19” revenue and revenue changes, revenue ex-COVID-19, “adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA” and “adjusted EBITDA margin” eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

 

QuidelOrtho

Consolidated Statements of Operations

(Unaudited)

(In millions except per share data)

 

 

Three Months Ended

 

March 31, 2024

 

April 2, 2023

Total revenues

$

711.0

 

 

$

846.1

Cost of sales, excluding amortization of intangibles

 

378.9

 

 

 

397.5

Selling, marketing and administrative

 

204.7

 

 

 

202.4

Research and development

 

59.2

 

 

 

62.3

Amortization of intangible assets

 

51.7

 

 

 

50.8

Acquisition and integration costs

 

22.6

 

 

 

29.7

Goodwill impairment charge

 

1,743.9

 

 

 

Other operating expenses

 

8.0

 

 

 

3.8

Operating (loss) income

 

(1,758.0

)

 

 

99.6

Interest expense, net

 

39.0

 

 

 

36.7

Other expense, net

 

1.9

 

 

 

2.9

(Loss) income before income taxes

 

(1,798.9

)

 

 

60.0

(Benefit from) provision for income taxes

 

(92.9

)

 

 

11.2

Net (loss) income

$

(1,706.0

)

 

$

48.8

Basic (loss) earnings per share

$

(25.50

)

 

$

0.73

Diluted (loss) earnings per share

$

(25.50

)

 

$

0.73

Weighted-average shares outstanding - basic

 

66.9

 

 

 

66.6

Weighted-average shares outstanding - diluted

 

66.9

 

 

 

67.1

 

QuidelOrtho

Condensed Consolidated Balance Sheets

(Unaudited)

(In millions)

 

 

March 31, 2024

 

December 31, 2023

Cash and cash equivalents

$

78.5

 

$

118.9

Marketable securities

 

 

 

48.4

Accounts receivable, net

 

271.7

 

 

303.3

Inventories

 

583.1

 

 

577.8

Prepaid expenses and other current assets

 

279.1

 

 

262.1

Property, plant and equipment, net

 

1,441.3

 

 

1,443.8

Marketable securities

 

 

 

7.4

Right-of-use assets

 

180.5

 

 

169.6

Goodwill

 

734.8

 

 

2,492.0

Intangible assets, net

 

2,887.3

 

 

2,934.3

Deferred tax asset

 

24.9

 

 

25.9

Other assets

 

222.1

 

 

179.6

Total assets

$

6,703.3

 

$

8,563.1

 

 

 

 

Accounts payable

$

249.6

 

$

294.8

Accrued payroll and related expenses

 

108.9

 

 

84.8

Income tax payable

 

9.5

 

 

11.1

Current portion of borrowings

 

161.1

 

 

139.8

Other current liabilities

 

250.7

 

 

303.3

Operating lease liabilities

 

181.8

 

 

172.8

Long-term borrowings

 

2,241.0

 

 

2,274.8

Deferred tax liability

 

125.6

 

 

192.2

Other liabilities

 

67.4

 

 

83.6

Total liabilities

 

3,395.6

 

 

3,557.2

Total stockholders’ equity

 

3,307.7

 

 

5,005.9

Total liabilities and stockholders’ equity

$

6,703.3

 

$

8,563.1

 

QuidelOrtho

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In millions)

 

 

Three Months Ended

 

March 31, 2024

 

April 2, 2023

Cash (used for) provided by operating activities

$

(0.7

)

 

$

188.9

 

Cash used for investing activities

 

(20.2

)

 

 

(68.9

)

Cash used for financing activities

 

(18.5

)

 

 

(59.6

)

Effect of exchange rates on cash

 

(1.1

)

 

 

0.6

 

Net (decrease) increase in cash, cash equivalents and restricted cash

 

(40.5

)

 

 

61.0

 

Cash, cash equivalents and restricted cash at beginning of period

 

119.5

 

 

 

293.9

 

Cash, cash equivalents and restricted cash at end of period

$

79.0

 

 

$

354.9

 

 

 

 

 

Reconciliation to amounts within the consolidated balance sheets:

 

 

 

Cash and cash equivalents

$

78.5

 

 

$

353.9

 

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Gyala: a new "Made in Italy" cybersecurity

With a proven track record in the defence field, Gyala now also brings its cybersecurity technologies to the wider enterprise audience

ITALIAN PROJECT AWARDS 2023: the best IT projects of the year, awarded

Now in its third edition, the initiative is targeted at the ICT professional world and honours projects based on innovative ideas and technologies, realised…

I3P launches the Cybersecurity Incubation Program

The I3P's initiative is promoted together with the National Cybersecurity Agency in collaboration with Leonardo and C*Sparks.

iVis Technologies enables remotely-controlled corneal telesurgery

It's based on Italian technologies the first successful intercontinental telesurgery intervention for keratoconus carried out remotely, connecting Bari…

Most read

NukuDo, a Global Leader in Cybersecurity Workforce Development, Launches…

Today, NukuDo, a global leader in cybersecurity workforce development and staffing, proudly announces the launch of its North American headquarters in…

Latin America Data Center Market Landscape Report 2024-2029 Featuring…

The "Latin America Data Center Market Landscape 2024-2029" report has been added to ResearchAndMarkets.com's offering. The Latin American data center…

TruBridge Announces Participation in the Stifel Cross Sector Insight Conference

TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate in the Stifel Cross Sector Insight Conference…

AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident…

AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG’s parent company…